Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE) is a cognitive-behavioral psychotherapy program designed for patients who have posttraumatic stress disorder (PTSD) and a co-occurring alcohol or drug use disorder.
Sudie E. Back, Ph.D., is a Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina, and a Staff Psychologist at the Ralph H. Johnson Veterans Affairs (VA) Medical Center in Charleston, SC. She is Director of the NIDA-sponsored Drug Abuse Research Training (DART) residency and summer research programs at the Medical University of South Carolina. Edna B. Foa, Ph.D., is a Professor of Clinical Psychology in Psychiatry at the University of Pennsylvania, and Director of the Center for the Treatment and Study of Anxiety. Dr. Foa devoted her academic career to study the psychopathology and treatment of anxiety disorders, primarily obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD). Therese K. Killeen, Ph.D., APRN, is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina. Dr. Killeen has over 20 years of experience working with adult and adolescent patients with comorbid PTSD and substance use disorders. Katherine L. Mills, Ph.D., is an Associate Professor at the National Drug and Alcohol Research Centre, University of New South Wales. Dr. Mills is also Director of Treatment Research for the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Mental Health and Substance Use in Australia. Maree Teesson, Ph.D., is a National Health and Medical Research Council (NHMRC) Senior Research Fellow at the National Drug and Alcohol Research Centre, University of New South Wales, and Director of the NHMRC Centre of Research Excellence in Mental Health and Substance Use in Australia. Bonnie Dansky Cotton, Ph.D., is a senior manager at Microsoft Corporation. She received her PhD in Clinical Psychology from Duke University and completed her internship at the Medical University of South Carolina. Prior to her career at Microsoft, Dr. Cotton was an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina. Kathleen M. Carroll, Ph.D., is the Albert E. Kent Professor of Psychiatry at Yale University School of Medicine. She is an internationally renowned researcher on the development of behavioral therapies for substance use disorders. Dr. Carroll is Principal Investigator of the Center for Psychotherapy Development at Yale and Co-Principal Investigator of the New England Consortium of NIDA's Clinical Trials Network. Kathleen T. Brady, MD, Ph.D., is a Distinguished University Professor and Associate Provost for Clinical and Translational Science at the Medical University of South Carolina. Dr. Brady is Director of the Women's Research Center, Director of the MUSC Clinical and Translational Research Center (CTSA), and Director of the Southern Consortium of NIDA's Clinical Trials Network.
Show moreConcurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE) is a cognitive-behavioral psychotherapy program designed for patients who have posttraumatic stress disorder (PTSD) and a co-occurring alcohol or drug use disorder.
Sudie E. Back, Ph.D., is a Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina, and a Staff Psychologist at the Ralph H. Johnson Veterans Affairs (VA) Medical Center in Charleston, SC. She is Director of the NIDA-sponsored Drug Abuse Research Training (DART) residency and summer research programs at the Medical University of South Carolina. Edna B. Foa, Ph.D., is a Professor of Clinical Psychology in Psychiatry at the University of Pennsylvania, and Director of the Center for the Treatment and Study of Anxiety. Dr. Foa devoted her academic career to study the psychopathology and treatment of anxiety disorders, primarily obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD). Therese K. Killeen, Ph.D., APRN, is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina. Dr. Killeen has over 20 years of experience working with adult and adolescent patients with comorbid PTSD and substance use disorders. Katherine L. Mills, Ph.D., is an Associate Professor at the National Drug and Alcohol Research Centre, University of New South Wales. Dr. Mills is also Director of Treatment Research for the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Mental Health and Substance Use in Australia. Maree Teesson, Ph.D., is a National Health and Medical Research Council (NHMRC) Senior Research Fellow at the National Drug and Alcohol Research Centre, University of New South Wales, and Director of the NHMRC Centre of Research Excellence in Mental Health and Substance Use in Australia. Bonnie Dansky Cotton, Ph.D., is a senior manager at Microsoft Corporation. She received her PhD in Clinical Psychology from Duke University and completed her internship at the Medical University of South Carolina. Prior to her career at Microsoft, Dr. Cotton was an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina. Kathleen M. Carroll, Ph.D., is the Albert E. Kent Professor of Psychiatry at Yale University School of Medicine. She is an internationally renowned researcher on the development of behavioral therapies for substance use disorders. Dr. Carroll is Principal Investigator of the Center for Psychotherapy Development at Yale and Co-Principal Investigator of the New England Consortium of NIDA's Clinical Trials Network. Kathleen T. Brady, MD, Ph.D., is a Distinguished University Professor and Associate Provost for Clinical and Translational Science at the Medical University of South Carolina. Dr. Brady is Director of the Women's Research Center, Director of the MUSC Clinical and Translational Research Center (CTSA), and Director of the Southern Consortium of NIDA's Clinical Trials Network.
Show moreChapter 1: Introductory Information for Therapists
Chapter 2: Outline of this Treatment Program
Chapter 3: Session 1: Introduction to COPE
Chapter 4: Session 2: Common Reactions to Truama and Craving
Awareness
Chapter 5: Session 3: Developing the In Vivo Hierarchy and Craving
Management
Chapter 6: Session 4: Initial Imaginal Exposure
Chapter 7: Session 5: Imaginal Exposure Continued and Planning and
Emergencies
Chapter 8: Session 6: Imaginal Exposure Continued and Awareness of
High-Risk Thoughts
Chapter 9: Session 7: Imaginal Exposure Continued and Managing
High-Risk Thoughts
Chapter 10: Session 8: Imaginal Exposure Continued and Refusal
Skills
Chapter 11: Session 9: Imaginal Exposure Continued and Seemingly
Irrelevant Decisions (SIDs)
Chapter 12: Session 10: Imaginal Exposure Continued and Anger
Awareness
Chapter 13: Session 11: Final Imaginal Exposure and Anger
Management
Chapter 14: Session 12: Review and Termination
Appendix A: Information Gathering Form
Appendix B: Safety Agreement
Appendix C: Therapist Imaginal Exposure Recording Form
Appendix D: Certificate of Completion
References
About the Authors
Sudie E. Back, Ph.D., is a Professor in the Department of
Psychiatry and Behavioral Sciences at the Medical University of
South Carolina, and a Staff Psychologist at the Ralph H. Johnson
Veterans Affairs (VA) Medical Center in Charleston, SC. She is
Director of the NIDA-sponsored Drug Abuse Research Training (DART)
residency and summer research programs at the Medical University of
South Carolina.
Edna B. Foa, Ph.D., is a Professor of Clinical Psychology in
Psychiatry at the University of Pennsylvania, and Director of the
Center for the Treatment and Study of Anxiety. Dr. Foa devoted her
academic career to study the psychopathology and treatment of
anxiety disorders, primarily obsessive-compulsive disorder (OCD)
and post-traumatic stress disorder (PTSD).
Therese K. Killeen, Ph.D., APRN, is an Associate Professor in the
Department of Psychiatry and Behavioral Sciences at the Medical
University of South Carolina. Dr. Killeen has over 20 years of
experience working with adult and adolescent patients with comorbid
PTSD and substance use disorders.
Katherine L. Mills, Ph.D., is an Associate Professor at the
National Drug and Alcohol Research Centre, University of New South
Wales. Dr. Mills is also Director of Treatment Research for the
National Health and Medical Research Council (NHMRC) Centre of
Research Excellence in Mental Health and Substance Use in
Australia.
Maree Teesson, Ph.D., is a National Health and Medical Research
Council (NHMRC) Senior Research Fellow at the National Drug and
Alcohol Research Centre, University of New South Wales, and
Director of the NHMRC Centre of Research Excellence in Mental
Health and Substance Use in Australia.
Bonnie Dansky Cotton, Ph.D., is a senior manager at Microsoft
Corporation. She received her PhD in Clinical Psychology from Duke
University and completed her internship at the Medical University
of South Carolina. Prior to her career at Microsoft, Dr. Cotton was
an Assistant Professor in the Department of Psychiatry and
Behavioral Sciences at the Medical University of South
Carolina.
Kathleen M. Carroll, Ph.D., is the Albert E. Kent Professor of
Psychiatry at Yale University School of Medicine. She is an
internationally renowned researcher on the development of
behavioral therapies for substance use disorders. Dr. Carroll is
Principal Investigator of the Center for Psychotherapy Development
at Yale and Co-Principal Investigator of the New England Consortium
of NIDA's Clinical Trials Network.
Kathleen T. Brady, MD, Ph.D., is a Distinguished University
Professor and Associate Provost for Clinical and Translational
Science at the Medical University of South Carolina. Dr. Brady is
Director of the Women's Research Center, Director of the MUSC
Clinical and Translational Research Center (CTSA), and Director of
the Southern Consortium of NIDA's Clinical Trials Network.
"Co-morbidity of PTSD and substance use disorders is as challenging
as it is common in clinical practice. COPE offers the first
integrated approach to treatment of these patients that has a solid
foundation in evidence-based techniques and applies insights from
basic neuroscience. Our experience with COPE for PTSD patients with
alcohol addiction has been truly amazing." -- Markus Heilig, MD
PhD, Chief, Lab of Clinical and Translational Studies, NIAAA
"COPE is a much-needed integrated treatment for substance use and
posttraumatic stress disorders. This excellent therapist manual,
and its accompanying patient workbook, will provide important
guidance for clinicians in delivering COPE, thereby expanding the
possibility of providing high-quality integrated care for
individuals suffering from both of these illnesses." --Shelly F.
Greenfield, MD, MPH, Chief Academic Officer, Chief, Division of
Women's Mental
Health, and Director of Clinical and Health Services Research and
Education, Division of Alcohol and Drug Abuse, McLean Hospital, and
Professor of Psychiatry, Harvard Medical School
"COPE is a long awaited and much needed treatment manual, developed
by an outstanding group of clinicians and researchers. COPE will
allow exposure therapy, a highly effective treatment for PTSD, to
be more readily available to patients who also have a substance use
disorder. I recommend this book to anyone who treats patients who
have both PTSD and a substance use disorder." --Sonya B. Norman,
PhD, Associate Professor, Department of Psychiatry, University
of
California, San Diego
"This pair of books brings science-based treatment techniques and
skills to a population of clients and therapists in urgent need.
Based on years of careful and systematic development, these books
provide critical training in how to deliver prolonged exposure
therapy techniques in those with substance addictions. They are a
groundbreaking addition to any trauma and addiction therapist's
treatment collection." --Denise Hien, PhD, ABPP, Professor of
Clinical
Psychology, City College, Graduate Center of the City University of
New York
"Clinicians who work with patients with PTSD and a co-occurring
alcohol or drug-use disorder will benefit substantially from this
book. This would also be an excellent teaching tool for
graduate-level courses such as advanced treatment techniques and
psychotherapy. The Treatments That Work series provides timely and
useful additions to the field. The incidence and prevalence of PTSD
and concurrent substance use disorder is more than enough reason
for
this book and it will be invaluable in treatment." --Nicholas Greco
IV, Doody's Health Science Book Review
Featured in PsycCRITIQUES
|
Ask a Question About this Product More... |
|
